The design and discovery of topoisomerase-II inhibitors as new cancer drugs: current strategies and future perspectives [0.03%]
DNA拓扑异构酶抑制剂作为新型抗肿瘤药物的设计与发现：目前策略及未来展望
Prasanna Anjaneyulu Yakkala,Rahaman Shaik,Bhusi Reddy Seelam et al.
Prasanna Anjaneyulu Yakkala et al.
Introduction: Topoisomerases (Topo) are important targets in cancer chemotherapy due to their essential role in regulating DNA topology. Clinically used topoisomerase inhibitors, including poisons and catalytic inhibitors...
Animal models that mirror bipolar disorder's pathophysiologic complexities: focused review of common models [0.03%]
反映双相障碍病理生理复杂性的动物模型：常见模型的综述性研究
Ramy Yassa,Muhammad Ibrahim,Rif S El-Mallakh
Ramy Yassa
Introduction: It is difficult to model bipolar disorder in animals because the illness has opposed behavioral expressions and a multitude of associated pathophysiologic anomalies. ...
Artificial intelligence in antimicrobial drug discovery: predictive and generative strategies [0.03%]
人工智能在抗菌药物发现中的预测和生成策略
Ximeng Duan,Na Liu,Lin Liu et al.
Ximeng Duan et al.
Introduction: The slow pipeline of antimicrobial drug development stands in stark contrast to the continued expansion of microbial infections, which pose a persistent and major threat to global public health. Traditional ...
The design of multi-target ligands and their role in schizophrenia therapy: an update [0.03%]
多靶点配体的设计及其在精神分裂症治疗中的作用：最新研究进展
Zarko Gagic,Marija Popovic-Nikolic,Marija Carapic et al.
Zarko Gagic et al.
Introduction: Schizophrenia is a complex psychiatric disorder with a partially understood pathophysiology involving multiple neurotransmitter systems and receptor families in its onset and progression. Modern therapeutic ...
The application of fluorinated α-amino acids to drug discovery techniques [0.03%]
含氟α-氨基酸在药物发现技术中的应用
Paul Richardson
Paul Richardson
Introduction: While fluorinated amino acids (FAAs) have been utilized for the discovery and development of both small molecules and therapeutic peptides, it is important to also recognize the stand-alone value of these en...
Multi-target approaches to prion disease Drug discovery: a status update [0.03%]
朊病毒疾病药物发现的多靶标方法研究进展：现状更新
Lea Nikolić,Giuseppe Legname
Lea Nikolić
Introduction: Prion diseases comprise a heterogeneous group of rare and fatal neurodegenerative disorders characterized by self-propagating misfolding of the cellular prion protein. Although no therapy has yet proven capa...
Marine metabolomics for bioactive material discovery: current trends, challenges, and future perspectives [0.03%]
海洋代谢组学在生物活性物质发现中的应用：现状、挑战与未来前景
Jia-Hui Ma,Fazlurrahman Khan,Young-Mog Kim et al.
Jia-Hui Ma et al.
Introduction: Marine metabolomics has emerged as a powerful approach for elucidating the chemical basis of marine biodiversity, ecological interactions, and organismal responses to environmental change. By profiling low-m...
Therapeutic targeting of adhesion GPCRs: a status update and future potential [0.03%]
粘附G蛋白偶联受体的治疗靶向：最新进展和未来潜力
Jesse D Stillwell,Maryam Ahmadian Elmi,Rashed R Parag et al.
Jesse D Stillwell et al.
Introduction: Adhesion G-Protein Coupled Receptors (aGPCRs) represent the second largest GPCR family and consist of 32 members in humans, of which 19 are orphan receptors. Despite making up a substantial portion of GPCRs,...
In vitro prediction of the immunogenicity of therapeutic proteins: state of the art and current challenges and perspectives [0.03%]
治疗性蛋白质免疫原性体外预测研究：现状、挑战与展望
Olivier Fardel,Emna Mahfoudhi,Laurence Launay et al.
Olivier Fardel et al.
Introduction: Immunogenicity of therapeutic proteins is a major concern because it may compromise their clinical use and efficacy. Preclinical prediction of anti-drug antibody development using in vitro assays is therefor...
The root cause: why do so many drugs fail to translate from bench to bedside? [0.03%]
根本原因：为何有那么多药物无法从实验台走向临床？
Andre Levchenko,Mark Corrigan,Bruce Wexler
Andre Levchenko